Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
- PMID: 24375332
- PMCID: PMC3946917
- DOI: 10.1002/cncr.28352
Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
Abstract
Background: Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI.
Methods: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks.
Results: The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores.
Conclusions: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study.
Keywords: acupuncture; aromatase inhibitor; musculoskeletal symptoms; patient-reported outcomes.
© 2013 American Cancer Society.
Conflict of interest statement
Dr. Saranya Chumsri has consultant/advisory role in Novartis, and receives research funding from Novartis, GSK, Merck; Dr. Vered Stearns receives research funding from Pfizer, Novartis.
Figures





Similar articles
-
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.Cancer. 2014 Dec 1;120(23):3744-51. doi: 10.1002/cncr.28917. Epub 2014 Jul 30. Cancer. 2014. PMID: 25077452 Free PMC article. Clinical Trial.
-
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.Breast Cancer Res Treat. 2013 Feb;138(1):167-74. doi: 10.1007/s10549-013-2427-z. Epub 2013 Feb 8. Breast Cancer Res Treat. 2013. PMID: 23393007 Free PMC article. Clinical Trial.
-
Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.J Clin Oncol. 2010 Mar 1;28(7):1154-60. doi: 10.1200/JCO.2009.23.4708. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100963 Clinical Trial.
-
Acupuncture for joint symptoms related to aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer: a narrative review.Acupunct Med. 2015 Jun;33(3):188-95. doi: 10.1136/acupmed-2014-010735. Epub 2015 Mar 2. Acupunct Med. 2015. PMID: 25733539 Review.
-
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
Cited by
-
Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies.J Pain Res. 2025 Apr 7;18:1853-1889. doi: 10.2147/JPR.S492891. eCollection 2025. J Pain Res. 2025. PMID: 40226826 Free PMC article. Review.
-
Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis.PLoS One. 2017 Aug 22;12(8):e0180918. doi: 10.1371/journal.pone.0180918. eCollection 2017. PLoS One. 2017. PMID: 28829776 Free PMC article.
-
Effects of acupuncture on improving sleep quality and the risk of emotional maladjustment of breast cancer patients: a systematic review and meta-analysis.Front Oncol. 2025 Jun 26;15:1617818. doi: 10.3389/fonc.2025.1617818. eCollection 2025. Front Oncol. 2025. PMID: 40641922 Free PMC article.
-
RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.PLoS One. 2015 Jul 28;10(7):e0133964. doi: 10.1371/journal.pone.0133964. eCollection 2015. PLoS One. 2015. PMID: 26218592 Free PMC article.
-
Acupuncture for Neoplasms: An Update from the PubMed Database.Med Acupunct. 2015 Jun 1;27(3):151-157. doi: 10.1089/acu.2014.1077. Med Acupunct. 2015. PMID: 26155320 Free PMC article. Review.
References
-
- Burstein HJ, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(23):3784–96. - PMC - PubMed
-
- Morales L, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004;15(8):753–60. - PubMed
-
- Fallowfield L, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(21):4261–71. - PubMed
-
- Fallowfield LJ, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(6):910–7. - PubMed
-
- Whelan TJ, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(28):6931–40. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous